Generic name: Valdecoxib (known as non-steroidal anti-inflammatory drugs or NASAIDS)
Manufactured and marketed by: Pfizer
Purpose: It was prescribed to deal with symptoms of osteoarthritis, rheumatoid arthritis and painful menstrual cycles.
Recall: On April 7, 2005, the FDA requested that Pfizer voluntarily remove Bextra from the United States market, due to the drug’s link to significant negative side effects. It was requested that Bextra be removed from the market because the FDA found that the overall risk of taking Bextra surpassed any benefit that the drug may provide.
If you have suffered a life-altering injury from taking Bextra, complete this form for free evaluation.
Side Effects Reported
- Bextra is linked to serious cardiovascular side effects like heart attack and stroke. Bextra has also been linked to very serious skin problems including toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme.
- Some of the skin condition side effects may be potentially fatal. European regulators have also made Bextra unavailable in the European Union market.
- Physicians have been advised to have those patients who are treated with Bextra moved to alternative medications for their needs.
In 2004, the New York Times reported that a study of Bextra conducted by the American Heart Association found that there were 2.19 times as many heart attacks and strokes reported amongst patients given Bextra than those patients given a placebo. The data was compiled from 12 trials involving a total of 5,930 patients.